(A-NEE-mee-a) A condition in which the number of red blood cells is below normal.
Reduces the redness, swelling, and pain that is a result of the body’s reaction to irritation or injury.
(Aut- + -ologous He-ma-to-poi-et-ic Stem Sel Trans-plan-ta-shen) A blood or bone marrow transplant that replaces abnormal blood-forming stem cells with healthy cells.
(B-LIM-foh-sites) A type of white blood cell that is made in the bone marrow and grows into a plasma cell.
All signs and symptoms of the cancer have disappeared, but cancer may still be in the body.
(Throm-BOH-sis) A blood clot inside a blood vessel.
(dee-hi-DRA-shuhn) A condition that occurs when the body loses too much water.
Swelling caused by fluids in your body’s tissues.
A network of cells and organs that protects the body from disease organisms, other foreign bodies, and cancers.
Any drug that has an effect on the immune system's ability to fight cancer cell growth.
In a test tube or glass; outside of a living organism.
(M PROH-teen) A type of antibody found in the body or urine of people with multiple myeloma.
Treatment that is given to help keep multiple myeloma from coming back following an initial therapy such as an autologous hematopoietic stem cell transplantation.
Myeloma cells that build up in the bone marrow and crowd out normal blood cells.
(NOO-tro-PEE-nee-uh) A condition in which the number of neutrophils (the most numerous type of white blood cells, which help fight infection) is below normal in the blood.
(NOO-tro-fils) A type of white blood cell that is one of the first types of cells to travel to the site of an infection.
The percentage of patients who respond to a specific therapy in a clinical trial with a partial response or better.
The percentage of patients alive after a given amount of time as specified in the clinical trial.
A treatment outcome where there is greater than 50% decrease in M protein.
An inactive treatment that is used in clinical trials to compare its effects with the active treatment, or standard of care. It looks like the active treatment and is given the same way.
A type of white blood cell. Plasma cells make substances that fight infections.
(PLATE-lets) Blood cells that are essential for blood clotting.
The length of time a patient lives with the disease without the disease getting worse.
(Proo-RY-tus) A clinical term for itching.
A pulmonary embolism happens when one or more blood clots travel to the lungs. The blood clots usually travel up from larger veins in the legs and pelvis.
Cells that carry oxygen to the body’s tissues.
Myeloma cells that remain after treatment or attempts to remove the cancer.
An unintended reaction to, or result of, a treatment.
(THROM-boh-sy-toh-PEE-nee-uh) A condition in which there are too few platelets in the blood. It may lead to easy bruising and bleeding.
The length of time a patient was on therapy before their multiple myeloma started to get worse.
(TOO-mer LY-sis SIN-drome) Metabolic complications that can occur during treatment of cancer and sometimes even without treatment. The complications are caused by the breakdown products of dying cancer cells and may include the following changes to blood chemistry: higher levels of potassium, phosphorus, and uric acid, and lower levels of calcium. These changes can lead to changes in kidney function and/or heartbeat, seizures, and sometimes death.
Treatment outcome where there is a greater than 90% decrease in M protein; also known as very good partial remission.
A type of cell that is found in the blood and lymph tissue that helps fight infections and diseases.